# Safety, Tolerability and Fat Absorption Using Enteral Feeding In-line Enzyme Cartridge (Relizorb)

> **NCT02598128** · NA · COMPLETED · sponsor: **Alcresta Therapeutics, Inc.** · enrollment: 34 (actual)

## Conditions studied

- Exocrine Pancreatic Insufficiency

## Interventions

- **DEVICE:** RELiZORB
- **DEVICE:** Placebo

## Key facts

- **NCT ID:** NCT02598128
- **Lead sponsor:** Alcresta Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-11
- **Primary completion:** 2016-06
- **Final completion:** 2016-06
- **Target enrollment:** 34 (ACTUAL)
- **Last updated:** 2017-01-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02598128

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02598128, "Safety, Tolerability and Fat Absorption Using Enteral Feeding In-line Enzyme Cartridge (Relizorb)". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02598128. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*